Empagliflozin (SGLT2i)
em-pa-gli-FLOH-zin
USAN
IUPAC Empagliflozin
SMILES
C1CC(OC1)OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
A+
90.0/100
Evidence Summary
SGLT2 inhibitors (empagliflozin, dapagliflozin) are the highest-evidence longevity compound class in the registry, with A+ grades for both CKD and heart failure indications. The EMPA-KIDNEY, DAPA-CKD, and CREDENCE trials demonstrated significant reductions in kidney disease progression and cardiovascular death.
Unlike most longevity interventions, SGLT2 inhibitors have multiple completed Phase 3 RCTs with hard clinical endpoints across multiple indications. They are FDA-approved and widely prescribed.
SGLT2 inhibitors receive less consumer attention than GLP-1 agonists despite comparable or superior clinical evidence for organ-specific outcomes — a key example of the evidence-hype gap this platform exists to surface.
Unlike most longevity interventions, SGLT2 inhibitors have multiple completed Phase 3 RCTs with hard clinical endpoints across multiple indications. They are FDA-approved and widely prescribed.
SGLT2 inhibitors receive less consumer attention than GLP-1 agonists despite comparable or superior clinical evidence for organ-specific outcomes — a key example of the evidence-hype gap this platform exists to surface.
Safety Considerations
Genital mycotic infections (common). Diabetic ketoacidosis risk (rare, even in non-diabetics). Volume depletion risk in elderly or those on diuretics. Fournier gangrene (extremely rare). Monitor renal function. Not recommended in advanced CKD (eGFR <20).
Evidence Signals (0)
Products Containing Empagliflozin (SGLT2i)
No commercial products are currently listed for this molecule.
Regulatory Intelligence
This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.